Gefitinib [cytosol]

Stable Identifier
Iressa, ZD1839, Reversible tyrosine kinase inhibitor gefitinib EGFR specific
Locations in the PathwayBrowser

Gefitinib (ZD1839, Iressa) is a low-molecular-weight EGFR tyrosine kinase inhibitor (TKI) from the anilinoquinazoline class of TKIs, developed by AstraZeneca Pharmaceuticals. Gefitinib selectively inhibits EGFR-stimulated tumor cell growth and blocks EGFR autophosphorylation in tumor cells by competitive inhibition of ATP binding to kinase domain of EGFR (Wakeling et al. 2002, Yun et al. 2007).

Literature References
PubMed ID Title Journal Year
17349580 Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity

Yun, CH, Boggon, TJ, Li, Y, Woo, MS, Greulich, H, Meyerson, M, Eck, MJ

Cancer Cell 2007
12384534 ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy

Wakeling, AE, Guy, SP, Woodburn, JR, Ashton, SE, Curry, BJ, Barker, AJ, Gibson, KH

Cancer Res 2002
Participant Of
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Cross References
Cite Us!